ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 029,68
0,91%
Dow Jones
38 675,68
0,00%
DAX
18 193,63
1,11%
Brent Oil
83,335
0,25%
Bitcoin
63 766,84
-0,36%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. USOTC
  6. Revive Therapeutics Ltd (QB) (RVVTF)

  7. Revive Therapeutics Ltd (QB) (RVVTF) Actualités

RVVTF

Revive Therapeutics (QB) (RVVTF)

Revive Therapeutics Ltd (QB)
De:
Trier par:
 Showing the most relevant articles for your search:USOTC:RVVTF
DateHeureSourceTitreSymboleSociété
18/04/202216h26InvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
12/04/202214h00InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
24/02/202214h35InvestorsHub NewsWireHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical ResearchUSOTC:RVVTFRevive Therapeutics Ltd (QB)
16/02/202214h03InvestorsHub NewsWireRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver TransplantationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/01/202215h13InvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
07/01/202214h05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
16/11/202114h00InvestorsHub NewsWireRevive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/09/202113h30InvestorsHub NewsWireRevive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETFUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/08/202112h00InvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerUSOTC:RVVTFRevive Therapeutics Ltd (QB)
12/08/202115h56InvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
10/08/202114h52InvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
15/07/202120h47InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
28/06/202114h00InvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/06/202114h59InvestorsHub NewsWireRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of PsychedelicsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
08/06/202115h12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/05/202115h48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripUSOTC:RVVTFRevive Therapeutics Ltd (QB)
03/05/202115h32InvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
27/04/202115h51InvestorsHub NewsWireRevive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain InjuryUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/04/202114h26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contUSOTC:RVVTFRevive Therapeutics Ltd (QB)
24/03/202114h15InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
19/03/202112h56InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
26/02/202115h01InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/02/202115h53InvestorsHub NewsWireRevive Therapeutics Acquires Unique Psilocybin AssetsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
11/02/202114h05InvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
27/01/202114h13InvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/01/202115h51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesUSOTC:RVVTFRevive Therapeutics Ltd (QB)
14/01/202114h30InvestorsHub NewsWireRevive Therapeutics Announces Research Collaboration with North Carolina State UniversityUSOTC:RVVTFRevive Therapeutics Ltd (QB)
31/12/202014h30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyUSOTC:RVVTFRevive Therapeutics Ltd (QB)
23/12/202015h57InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for BucillamineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/12/202017h05InvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
 Showing the most relevant articles for your search:USOTC:RVVTF

Dernières Valeurs Consultées

EU
RNO
Renault
FTSE
UKX
FTSE 100
EU
CAP
Capgemini
NASDAQ
MSFT
Microsoft
EU
AF
Air FranceKLM
EU
BEL20
Bel 20
EU
ORA
Orange
NASDAQ
GOOGL
Alphabet
NYSE
MCD
McDonalds
NASDAQ
NVDA
NVIDIA
EU
GLE
Societe Generale
NYSE
DIS
Walt Disney
EU
AI
Air Liquide
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés